CDK7 and neoplasm: These findings raise the possibility that tumours with increased expression of CDK7 may be more sensitive to CDK7 inhibition, particularly in the case of ER+ breast cancer, where the CDK7-activated nuclear receptor, ER⍺, drives tumour progression.